Abstract: The compounds of formula (I) where the group —R may represent ?O or —H, are new anti-proliferative agents with remarkable anti-tumour effects in-vivo, showing in particular a wide spectrum of activities in respect of lymphomas of different origin.
Type:
Grant
Filed:
March 26, 2018
Date of Patent:
October 18, 2022
Assignee:
FONDAZIONE PER L'ISTITUTO ONCOLOGICO DI RICERCA (IOR)
Inventors:
Eugenio Gaudio, Francesco Bertoni, Natalina Pazzi, Matilde Guala
Abstract: The present invention provides a method of treatment of prostate cancer, comprising administering a therapeutically effective amount of an inhibitor of IL-23 and/or an inhibitor of IL-23R to a mammalian patient in need thereof. The prostate cancer may be castration resistant prostate cancer (CRPC). The inhibitor may, for example, be an anti-IL-23 antibody, such as risankizumab, guselkumab or tildrakizumab. The method of treatment may further comprise administration of androgen deprivation therapy, such as enzalutamide. Also provided is a method of predicting the development of resistance to androgen deprivation therapy (ADT) in a prostate cancer in a mammalian patient and a related screening method.
Type:
Grant
Filed:
September 18, 2019
Date of Patent:
November 9, 2021
Assignees:
FONDAZIONE PER L'ISTITUTO ONCOLOGICO DI RICERCA (IOR), THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL
Inventors:
Andrea Alimonti, Arianna Calcinotto, Johann de Bono
Abstract: The present invention relates to the use of ALK tyrosine-kinase receptor inhibitors, in particular Alectinib, and compositions including it, as senolytic drug. In particular it relates to the use as senolytic drugs in a method of treatment of tumour or other pathological and incapacitating conditions associated to the cellular senescence.
Type:
Application
Filed:
January 15, 2019
Publication date:
December 31, 2020
Applicant:
FONDAZIONE PER L'ISTITUTO ONCOLOGICO DI RICERCA (IOR)
Inventors:
Manuel COLUCCI, Ajinkya REVANDKAR, Andrea ALIMONTI
Abstract: The present invention provides a method of treatment of prostate cancer, comprising administering a therapeutically effective amount of an inhibitor of IL-23 and/or an inhibitor of IL-23R to a mammalian patient in need thereof. The prostate cancer may be castration resistant prostate cancer (CRPC). The inhibitor may, for example, be an anti-IL-23 antibody, such as risankizumab, guselkumab or tildrakizumab. The method of treatment may further comprise administration of androgen deprivation therapy, such as enzalutamide. Also provided is a method of predicting the development of resistance to androgen deprivation therapy (ADT) in a prostate cancer in a mammalian patient and a related screening method.
Type:
Application
Filed:
September 18, 2019
Publication date:
March 26, 2020
Applicants:
Fondazione per l'Istituto Oncologico di Ricerca (IOR), The Institute of Cancer Research: Royal Cancer Hospital
Inventors:
Andrea Alimonti, Arianna Calcinotto, Johann de Bono